Compliance
Should your peptide company be the merchant of record?
For most peptide platforms, the answer is no. Being the merchant of record for the drug can make you look like the seller — and trigger 503B, anti-kickback, and corporate-practice-of-medicine risk.
Peptide Merchant Services — Compliance
Should your peptide company be the merchant of record?
For most peptide platforms, the answer is no. Being the merchant of record for the drug can make you look like the seller — and trigger 503B, anti-kickback, and corporate-practice-of-medicine risk.
Updated June 8, 2026 · 6 min read · https://peptidemerchantadvocates.com/resources/peptide-merchant-of-record
The short answer
In the cleanest model the regulated seller (FDA-approved manufacturer, licensed wholesaler, 503B facility, or 503A pharmacy) is the merchant of record, and your company is the compliance platform, billing agent, logistics coordinator, or GPO-like facilitator. Being the merchant of record for the drug can make you look like the seller and trigger 503B-wholesaling, fee-splitting, anti-kickback, and corporate-practice-of-medicine risk.
What is the "merchant of record," and why does it matter?
The merchant of record is the party that legally sells the product and accepts the payment for it. For a drug, that designation carries regulatory weight: if you are the merchant of record, regulators and acquirers may treat you as the seller of the medicine — with all the licensing and pathway obligations that implies.
The risks of being the merchant of record for the drug
Taking that role on for the drug itself opens several exposures at once:
- If you are the merchant of record, you may look like the seller of the drug — inheriting its pathway and licensing obligations.
- If you take title to 503B products and resell them, you may trigger the 503B wholesaling problem.
- If you collect patient money for a physician's clinical service, you may trigger fee-splitting, corporate-practice-of-medicine, anti-kickback (AKS), Stark, or state consumer-protection risk.
- If you bundle software, marketing, patient referrals, payments, and product supply, regulators may view the business as steering prescriptions.
The bankable structure
Regulated entities sell regulated products; your company supplies audited infrastructure and earns fixed, fair-market-value fees that are not tied to prescription volume where healthcare-fraud laws are implicated.
This is also the structure acquirers prefer, because it puts the licensed party on the hook for the drug and positions your company as the controls-and-payments layer — which is a fundamentally more boardable risk profile.
Key takeaways
- Default to NOT being the merchant of record for the drug.
- Let the regulated seller (manufacturer, wholesaler, 503B, 503A) be the seller of record.
- Be the compliance + payments infrastructure earning fixed, fair-market-value fees.
- Bundling supply, referrals, marketing, and payments invites a "steering prescriptions" read.
Frequently asked questions
Should my peptide platform be the merchant of record?
Usually no. The cleaner model keeps the regulated seller (manufacturer, licensed wholesaler, 503B facility, or 503A pharmacy) as the merchant of record while your company provides compliance and payments infrastructure for fixed, fair-market-value fees.
What happens if I take title to 503B products and resell them?
You may trigger the 503B wholesaling problem, because a 503B condition is that the compounded drug is only sold by the facility that compounded it.
Why can't I just collect the patient payment for the doctor?
Collecting patient money for a physician's clinical service can implicate fee-splitting, corporate-practice-of-medicine, anti-kickback, Stark, and state consumer-protection rules. Keep the clinical billing with the licensed provider.
Related compliance resources
More guidance on staying compliant and keeping payment processing in place.
- 10 things to know when selling BPC-157BPC-157 is one of the most searched peptides and one of the hardest to sell lawfully. Ten things every seller should understand about its regulatory status, marketing limits, and payment acceptance. 9 min read
- How to not get your peptide merchant account shut downA step-by-step operating playbook to keep a peptide merchant account boarded: what triggers a shutdown, the controls that prevent it, and the warning signs that mean you have days, not months. 10 min read
- How to legally run a peptide company in 2026A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file. 9 min read
- Is it legal to sell peptides? The four lawful pathwaysSelling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law. 8 min read
- 503A vs 503B for peptides: which compounding pathway fits?The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides. 7 min read
- Why "research use only" peptides can't be sold for human useSelling RUO or "not for human consumption" peptides into the physician-to-patient channel is one of the highest-risk models in the industry. Here is why — and what the FDA has said. 6 min read
This article is general educational information about regulatory frameworks (FDA, FTC, 503A/503B, DSCSA), not legal advice. Peptide compliance turns on product-specific and state-specific facts — review your model with qualified FDA, healthcare, and payments counsel before acting.
Keep reading
9 min read
How to legally run a peptide company in 2026
A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file.
8 min read
Is it legal to sell peptides? The four lawful pathways
Selling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law.
7 min read
503A vs 503B for peptides: which compounding pathway fits?
The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides.
Get a free statement review — no obligation.
We review your processing statement and flag every risk indicator underwriters will ask about. Back to you within 24 hours.